Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date: October 25, 2024
Event: Item 8.01 Other Events – Clinical Update on IDE397.
Context: The Company presented interim Phase 1 expansion data for IDE397, a potential first-in-class MAT2A inhibitor, at the ENA 2024 Symposium. The data focuses on patients with MTAP-deletion urothelial cancer and non-small cell lung cancer (NSCLC).
Key Financial Metrics
This filing is a clinical update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The filing reports preliminary clinical efficacy and safety data for IDE397 based on 27 evaluable patients at the 30 mg once-a-day expansion dose. Key clinical metrics include:
- Overall Response Rate (ORR): Approximately 33% (1 complete response, 8 partial responses) across all evaluable patients.
- Response by Tumor Type:
- Urothelial Cancer: 40% confirmed ORR (4/10 patients).
- Squamous NSCLC: ~38% confirmed ORR (3/8 patients).
- Adenocarcinoma NSCLC: ~22% confirmed ORR (2/9 patients).
- Disease Control Rate: 93% (25/27 patients).
- Molecular Response (ctDNA): ~81% of reportable patients showed ≥50% reduction; ~33% showed ≥90% reduction.
- Safety Profile: Approximately 18% of patients experienced Grade 3 or higher drug-related adverse events. No drug-related serious adverse events or discontinuations were observed.
- Duration: Median duration of treatment has not been reached (>6.2 months). Median time to response is ~2.7 months.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- Combination Therapy: The Company targets initiation of the IDE397 and Trodelvy (sacituzumab govitecan-hziy) Phase 1/2 combination expansion in MTAP-deletion urothelial cancer in Q4 2024.
- Monotherapy Expansion: Over 35 clinical trial sites are activated globally for the IDE397 Phase 2 monotherapy expansion in lung and bladder cancer.
- Market Opportunity: Estimated U.S. annual incidence for MTAP-deletion NSCLC and urothelial cancer is approximately 48,000 patients. Additional tumor types (pancreatic, head and neck, gastric, esophageal) represent an aggregate annual incidence of ~27,000 patients.
Risks and Contingencies:
- Data presented is preliminary and based on an unlocked database as of August 22, 2024.
- IDE397 and the combination with Trodelvy have not been approved by any regulatory agency.
- Forward-looking statements regarding clinical activity, enrollment timing, and regulatory filings involve substantial risks and uncertainties inherent in drug development.
Investor Verification Checklist
- Verify the final confirmed response rates once the database is locked and the full dataset is published.
- Monitor the actual initiation date of the IDE397 and Trodelvy Phase 1/2 combination trial in Q4 2024.
- Review the Company's cash runway and capital requirements in the most recent Form 10-K or 10-Q, as this 8-K does not disclose financial liquidity.
- Assess the long-term durability of responses, as median duration of response and progression-free survival data are currently immature.
- Confirm the status of the Amgen-sponsored Phase 1/2 trial (NCT05975073) for IDE397 and AMG 193 combination.